The rationale for the use of G3139 is based on the relevant role of bcl-2 in melanoma cell survival and on the increased sensitivity of this tumor when it is combined with chemotherapy, as it has been observed in preclinical and clinical studies (5-9). Here, BCL2 is linked to melanoma.